This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
6okq
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Crystal structure of the SF12 Fab== | |
| + | <StructureSection load='6okq' size='340' side='right'caption='[[6okq]], [[Resolution|resolution]] 3.20Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[6okq]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6OKQ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6OKQ FirstGlance]. <br> | ||
| + | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6okq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6okq OCA], [http://pdbe.org/6okq PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6okq RCSB], [http://www.ebi.ac.uk/pdbsum/6okq PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6okq ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design and are potential therapeutic agents. We identified SF12 and related bNAbs with up to 62% neutralization breadth from an HIV-infected donor. SF12 recognized a glycan-dominated epitope on Env's silent face and was potent against clade AE viruses, which are poorly covered by V3-glycan bNAbs. A 3.3A cryo-EM structure of a SF12-Env trimer complex showed additional contacts to Env protein residues by SF12 compared with VRC-PG05, the only other known donor-derived silentface antibody, explaining SF12's increased neutralization breadth, potency, and resistance to Env mutation routes. Asymmetric binding of SF12 was associated with distinct N-glycan conformations across Env protomers, demonstrating intra-Env glycan heterogeneity. Administrating SF12 to HIV-1-infected humanized mice suppressed viremia and selected for viruses lacking the N448gp120 glycan. Effective bNAbs can therefore be raised against HIV-1 Env's silent face, suggesting their potential for HIV-1 prevention, therapy, and vaccine development. | ||
| - | + | Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope.,Schoofs T, Barnes CO, Suh-Toma N, Golijanin J, Schommers P, Gruell H, West AP Jr, Bach F, Lee YE, Nogueira L, Georgiev IS, Bailer RT, Czartoski J, Mascola JR, Seaman MS, McElrath MJ, Doria-Rose NA, Klein F, Nussenzweig MC, Bjorkman PJ Immunity. 2019 May 14. pii: S1074-7613(19)30194-3. doi:, 10.1016/j.immuni.2019.04.014. PMID:31126879<ref>PMID:31126879</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | [[Category: | + | </div> |
| - | [[Category: Barnes, C | + | <div class="pdbe-citations 6okq" style="background-color:#fffaf0;"></div> |
| - | [[Category: Bjorkman, P | + | == References == |
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Barnes, C O]] | ||
| + | [[Category: Bjorkman, P J]] | ||
| + | [[Category: Envelope]] | ||
| + | [[Category: Fab structure]] | ||
| + | [[Category: Hiv-1 broadly-neutralizing antibody]] | ||
| + | [[Category: Immune system]] | ||
| + | [[Category: Silent face]] | ||
Revision as of 22:52, 5 June 2019
Crystal structure of the SF12 Fab
| |||||||||||
